Clinical Report: Approaches to Implementing Cascade Genetic Testing

Overview

Cascade genetic testing remains underutilized. Recent studies highlight the importance of patient navigation and cost-reduction strategies in improving testing rates among at-risk relatives.

Background

Hereditary breast and ovarian cancer (HBOC) and Lynch syndrome (LS) affect approximately 1.24% of the US population. Despite evidence-based screening and risk-reduction strategies, these conditions are often underdiagnosed. Effective implementation of cascade genetic testing is crucial for identifying at-risk individuals.

Data Highlights

Data from recent studies indicate that 12.5% of cancer patients not selected based on risk harbored a germline pathogenic variant.

Key Findings

• 12.5% of cancer patients not selected based on risk harbored a germline pathogenic variant.
• Only a minority of at-risk relatives undergo cascade genetic testing, particularly in underserved populations.
• In the Assisted Cascade Testing via Outreach and Navigation initiative, 77% of contacted relatives completed testing.
• In the GIFT trial, 91% of enrolled relatives completed testing, but 70-80% of eligible probands were lost at each study step.
• Family dynamics accounted for 40% of the variation in testing decisions.
• The IGNITE-TX trial showed a significant increase in testing completion rates with navigator support and no-cost counseling/testing.

Clinical Implications

Understanding family dynamics may be essential in tailoring approaches to improve genetic testing uptake among at-risk relatives.

Conclusion

Continued research and innovative approaches are necessary to address the barriers to testing in diverse populations.

Related Resources & Content

1. JAMA Network Open, 2023 -- Differences in Cascade Genetic Testing Among Families With Hereditary Cancer Risk
2. The ASCO Post, 2020 -- Should Restrictions on Genetic Testing Be Loosened?
3. CDC, 2023 -- Tier 1 Genomics Applications and their Importance to Public Health
4. JAMA Network Open, 2023 -- A Multilevel Intervention to Identify Individuals for Genetic Testing and Treatment: The IGNITE-TX Pilot Randomized Clinical Trial
5. JAMA Network Open, 2023 -- Implementation Strategies in Cascade Genetic Testing—The Devil Is in the Details
6. the pathologist — Genetic Panel Testing: Points of View (Marilyn Bui)
7. the pathologist — The Power of Pedigree
8. Tier 1 Genomics Applications and their Importance to Public Health | CDC
9. A Multilevel Intervention to Identify Individuals for Genetic Testing and Treatment: The IGNITE-TX Pilot Randomized Clinical Trial | Oncology | JAMA Network Open | JAMA Network
10. Implementation Strategies in Cascade Genetic Testing—The Devil Is in the Details | Oncology | JAMA Network Open | JAMA Network